NO975555L - Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein - Google Patents

Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein

Info

Publication number
NO975555L
NO975555L NO975555A NO975555A NO975555L NO 975555 L NO975555 L NO 975555L NO 975555 A NO975555 A NO 975555A NO 975555 A NO975555 A NO 975555A NO 975555 L NO975555 L NO 975555L
Authority
NO
Norway
Prior art keywords
protein
vaccine
carrier
polysaccharidangite
free
Prior art date
Application number
NO975555A
Other languages
English (en)
Norwegian (no)
Other versions
NO975555D0 (no
Inventor
Moncef Mohamed Slaoui
Pierre Hauser
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27451300&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO975555(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9512827.8A external-priority patent/GB9512827D0/en
Priority claimed from GBGB9513443.3A external-priority patent/GB9513443D0/en
Priority claimed from GBGB9525657.4A external-priority patent/GB9525657D0/en
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of NO975555D0 publication Critical patent/NO975555D0/no
Publication of NO975555L publication Critical patent/NO975555L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
NO975555A 1995-06-07 1997-12-02 Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein NO975555L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US47263995A 1995-06-07 1995-06-07
GBGB9512827.8A GB9512827D0 (en) 1995-06-23 1995-06-23 Vaccines
GBGB9513443.3A GB9513443D0 (en) 1995-07-01 1995-07-01 Vaccines
GBGB9525657.4A GB9525657D0 (en) 1995-12-15 1995-12-15 Vaccines
PCT/EP1996/002436 WO1996040242A1 (fr) 1995-06-07 1996-06-04 Vaccins comprenant un conjugue antigene de polysaccharide-proteine porteuse et une proteine porteuse libre

Publications (2)

Publication Number Publication Date
NO975555D0 NO975555D0 (no) 1997-12-02
NO975555L true NO975555L (no) 1998-01-09

Family

ID=27451300

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975555A NO975555L (no) 1995-06-07 1997-12-02 Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein

Country Status (18)

Country Link
EP (2) EP0831901B2 (fr)
JP (2) JP4233113B2 (fr)
AT (2) ATE400295T1 (fr)
AU (1) AU695720B2 (fr)
BR (1) BR9608612A (fr)
CA (1) CA2221511C (fr)
CZ (1) CZ390297A3 (fr)
DE (2) DE69615362T3 (fr)
DK (1) DK1090642T3 (fr)
ES (2) ES2164251T5 (fr)
HU (1) HUP9802199A3 (fr)
IL (1) IL122431A0 (fr)
NO (1) NO975555L (fr)
NZ (1) NZ311000A (fr)
PT (1) PT1090642E (fr)
SI (1) SI1090642T1 (fr)
TR (1) TR199701547T1 (fr)
WO (1) WO1996040242A1 (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
TR199701547T1 (xx) * 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.
SK283565B6 (sk) * 1996-07-02 2003-09-11 Connaught Laboratories Limited Multivalentná imunogénna kompozícia a jej použitie
US6248334B1 (en) * 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6284250B1 (en) 1998-02-05 2001-09-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Simplified method for removing free protein during preparation of protein-polysaccharide conjugates and vaccines using restricted-access media
US7018637B2 (en) * 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
WO2000056360A2 (fr) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Vaccin
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
PL226184B1 (pl) 2001-01-23 2017-06-30 Aventis Pasteur Poliwalentna sprzezona szczepionka meningokokowa polisacharyd- bialko
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
US7927858B2 (en) 2002-11-01 2011-04-19 Glaxosmithkline Biologicals, S.A. Drying process
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
EP2172213B1 (fr) 2003-01-30 2013-04-03 Novartis AG Vaccins injectables contre les multiples serogroupes du meningocoque
EP2609919A3 (fr) 2003-09-26 2014-02-26 Exelixis, Inc. Modulateurs c-Met et produits d'utilisation
PL1961426T3 (pl) 2003-10-02 2012-03-30 Gsk Vaccines S R L Skojarzone szczepionki przeciwko zapaleniu opon mózgowo-rdzeniowych
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
SI1740217T1 (sl) 2004-04-30 2011-10-28 Novartis Ag Konjugirano meningokokno cepljenje
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0428394D0 (en) * 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
GB0502096D0 (en) 2005-02-01 2005-03-09 Chiron Srl Purification of streptococcal capsular polysaccharide
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
JP2008536515A (ja) 2005-04-18 2008-09-11 ノバルティス ヴァクシンズ アンド ダイアグノスティクス， インコーポレイテッド ワクチンの調製のためのｂ型肝炎ウイルス表面抗原の発現
KR20130122810A (ko) † 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
EP1931380A2 (fr) 2005-09-01 2008-06-18 Novartis Vaccines and Diagnostics GmbH & Co. KG Vaccination multiple comprenant des meningocoques du serogroupe c
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
ES2670231T3 (es) 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regímenes para inmunización con conjugados meningocócicos
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
PL2066344T3 (pl) 2006-09-07 2011-10-31 Glaxosmithkline Biologicals Sa Skojarzona szczepionka zawierająca inaktywowany wirus polio
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
JP5689064B2 (ja) 2008-10-27 2015-03-25 ノバルティス アーゲー 精製方法
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
BR112012009014B8 (pt) 2009-09-30 2022-10-04 Novartis Ag Processo para preparar conjugado de polissacarídeo capsular de s. aureus tipo 5 ou tipo 8 e molécula de transporte crm197, conjugado e composição imunogênica
RS56000B1 (sr) 2009-10-30 2017-09-29 Glaxosmithkline Biologicals Sa Prečišćavanje stafilokokus aureus tip 5 i tip 8 kapsuliranih saharida
JP5781542B2 (ja) 2009-12-30 2015-09-24 ノバルティス アーゲー Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
CA2793510A1 (fr) 2010-03-18 2012-02-16 Novartis Ag Vaccins adjuvantes contre le meningocoque de serogroupe b
ES2744471T3 (es) 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
GB201106340D0 (en) * 2011-04-14 2011-06-01 Isis Innovation Composition
WO2013038375A2 (fr) 2011-09-14 2013-03-21 Novartis Ag Procédés de production de glycoconjugués de saccharide-protéine
WO2013068949A1 (fr) 2011-11-07 2013-05-16 Novartis Ag Molécule porteuse comprenant un antigène spr0096 et un antigène spr2021
EP2592137A1 (fr) 2011-11-11 2013-05-15 Novartis AG Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
US10124051B2 (en) 2012-05-22 2018-11-13 Glaxosmithkline Biologicals Sa Meningococcus serogroup X conjugate
AU2013311702A1 (en) 2012-09-06 2015-02-19 Novartis Ag Combination vaccines with serogroup B meningococcus and D/T/P
ES2848048T3 (es) 2012-10-03 2021-08-05 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas
SG11201502599TA (en) 2012-10-12 2015-05-28 Glaxosmithkline Biolog Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
BR112015014250A2 (pt) 2012-12-18 2017-07-11 Glaxosmithkline Biologicals Sa método para imunizar um bebê, vacina de combinação e, kit
JP6359561B2 (ja) 2013-01-04 2018-07-18 オービーアイ ファーマ インコーポレイテッド 高い炭水化物抗原密度を有するワクチン及び新規サポニンアジュバント
CN104174019A (zh) * 2014-09-23 2014-12-03 成都康华生物制品有限公司 四价脑膜炎球菌多糖载体蛋白结合疫苗
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (fr) 2014-12-19 2016-06-22 Novartis AG Purification de polysaccharides capsulaires de streptocoques
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
EP3530285B1 (fr) 2016-10-20 2023-08-09 KM Biologics Co., Ltd. PROCÉDÉ DE PRODUCTION D'UN VACCIN CONJUGÉ HIB UTILISANT DU PRP
DE POIDS MOLÉCULAIRE REDUIT
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3799884A1 (fr) 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Compositions immunogènes
CA3201450A1 (fr) 2020-11-13 2022-05-19 Glaxosmithkline Biologicals Sa Transporteurs de proteine bacterienne et procedes de conjugaison

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4644059A (en) * 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
KR0158436B1 (ko) * 1989-12-14 1998-12-01 피에르 오. 페론 개선된 수막염균성 폴리사카라이드 결합체 백신
ZA937034B (en) * 1992-09-24 1995-06-23 Brigham & Womens Hospital Group B streptococcus type II and type V polysaccharide-protein conjugate vaccines
ES2126616T3 (es) * 1992-10-27 1999-04-01 American Cyanamid Co Vacuna pediatrica combinada, con una inmunogenecidad aumentada de cada componente de la vacuna.
TR199701547T1 (xx) * 1995-06-07 1998-03-21 Smithkline Beecham Biologicals S.A. Polisakarit antijen protein e�leni�i i�eren a��.

Also Published As

Publication number Publication date
WO1996040242A1 (fr) 1996-12-19
IL122431A0 (en) 1998-06-15
ES2164251T3 (es) 2002-02-16
SI1090642T1 (sl) 2008-12-31
TR199701547T1 (xx) 1998-03-21
MX9709732A (es) 1998-10-31
EP1090642A3 (fr) 2001-08-22
EP1090642B8 (fr) 2010-08-11
AU695720B2 (en) 1998-08-20
ATE205724T1 (de) 2001-10-15
DK1090642T3 (da) 2008-09-22
DE69615362D1 (de) 2001-10-25
AU6222196A (en) 1996-12-30
NO975555D0 (no) 1997-12-02
DE69637597D1 (de) 2008-08-21
ES2164251T5 (es) 2006-06-01
EP1090642B1 (fr) 2008-07-09
ES2308962T3 (es) 2008-12-16
CZ390297A3 (cs) 1998-05-13
BR9608612A (pt) 1999-05-04
DE69615362T3 (de) 2006-07-20
ATE400295T1 (de) 2008-07-15
CA2221511A1 (fr) 1996-12-19
JP4233113B2 (ja) 2009-03-04
EP0831901B2 (fr) 2005-12-07
CA2221511C (fr) 2013-01-08
EP0831901B1 (fr) 2001-09-19
EP1090642A2 (fr) 2001-04-11
PT1090642E (pt) 2008-09-09
DE69615362T2 (de) 2002-06-13
EP0831901A1 (fr) 1998-04-01
NZ311000A (en) 1999-04-29
JPH11507026A (ja) 1999-06-22
JP4653131B2 (ja) 2011-03-16
JP2007186524A (ja) 2007-07-26
HUP9802199A3 (en) 1999-07-28
HUP9802199A1 (hu) 1999-01-28

Similar Documents

Publication Publication Date Title
NO975555L (no) Vaksine omfattende polysakkaridangiten-proteinbærer-konjugat og fritt bærerprotein
ATE250937T1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
PT1296711E (pt) E7 de vph para o tratamento do virus do papiloma humano
BRPI0114994B8 (pt) composição de vacina
DE69627652D1 (de) Verbesserte meningokokken polysaccharid-konjugat vakzine
DK0969873T3 (da) Multiple carbonhydratholdige glycopeptid-antigener, vaccine indeholdende dem og anvendelse deraf
TR200001519T2 (tr) İnsanlardaki Spermatozoa'nın konsantrasyonu ve/veya hareket kabiliyetini artırmak için uygulanması gerekli yöntem ve ilaç terkipleri
BR0008076A (pt) 16-hidroxiestratrienos como estrogênios de efeito seletivo
TR199900770T2 (xx) Nazal poliplerin tedavisinde bir H+, K+-ATPase'�n kullan�lmas�.
SE9400524L (sv) Energipreparat
BR9611477A (pt) Polipeptìdeo ou glicopeptìdeo, composições aptas a estimular a imunidade, sequência, e vetor, de ácidos nucleicos, vetor de expressão, processo de preparação de um polipeptìdeo ou glicopeptìdeo, vacina polivalente contr5a o vìrus da dengue e composição antigênica
HUP9801917A2 (hu) Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
AU3868895A (en) Process for the preparation of furosemide
IL117564A0 (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
MX9710521A (es) Una composicion de vacuna comprendiendo un antigeno conjugado de polisacarido adsorbido en fosfato de aluminio.
RU96120655A (ru) Композиция для профилактики и лечения гриппа и орви
王德深 A PROPOSAL FOR THE INTERNATIONAL STANDARDIZATION OF THE NAMES OF ACUPUNCTURE POINTS
Salmon Am it (M.), Great and Small Poleis. Λ Study in the Relations between the Great Powers and the Small Cities in Ancient Greece
RU94020944A (ru) Средство для интраназальной профилактики гриппа
ES2069469A1 (es) Procedimiento para la preparacion de productos olorosos tipo ambar gris a partir de acidos comunicos.
GEU1999444Y (en) Medicinal Means “Barambo”
RU94024812A (ru) Способ профилактики полиомиелита на крайнем севере